Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameLuzhu Biotech-B
Stock Code02480
Company Full NameTo be extracted
Industry醫療保健
Principal Activities公司是一家致力于開發創新型人類疫苗和治療性生物制劑,以預防和控制傳染性疾病,并治療癌癥和自身免疫性疾病的生物技術公司。
Listing Date2023-05-08
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京市通州區工業開發區廣通街3號
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttp://www.luzhubiotech.com/
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo data

Offering Information

Offering Mechanism To be extracted
Offer PriceHK$ 32.80 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer PeriodTo be extracted
Global Offering SharesTo be extracted
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)To be confirmed
Stabilizing Manager (Greenshoe)—
Cornerstone Share46.1%
Clawback TiersTo be extracted
Reallocation OptionTo be confirmed
Total Global Offering SizeHK$ 34,072,640

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 200 HK$ 6,560
2 lots 400 HK$ 13,120
3 lots 600 HK$ 19,680
4 lots 800 HK$ 26,240
5 lots 1,000 HK$ 32,800
6 lots 1,200 HK$ 39,360
7 lots 1,400 HK$ 45,920
8 lots 1,600 HK$ 52,480
9 lots 1,800 HK$ 59,040

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway None
Avg Daily HK Mkt Cap ---
Est. Threshold ---
Analysis Result 无法确定入通路径

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted
First Day CloseHK$ 22.0
First Day OpenHK$ 31.5
First Day Change-32.93%
First Day Volume2796200.0
First Day Turnover76911300.0
Use of Proceeds
1、約58.2%(或140.7百萬港元)將主要用于核心產品LZ901的臨床開發、制造及商業化; 2、約22.1%(或53.4百萬港元)將主要用于K3的臨床開發及制造; 3、約16.1%(或38.8百萬港元)將主要用于建設于珠海的商業生產設施,其是大型、定制及不可拆卸的生產設施; 4、約3.6%(或8.7百萬港元)將主要用作營運資金及其他一般公司用途。

Underwriting Syndicate

Sole Sponsor (1)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Overall Coordinators (3)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 国泰君安证券(香港)有限公司 CE ABY236 建银国际金融有限公司 CE AJO225
Joint Bookrunners (14)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 国泰君安证券(香港)有限公司 CE ABY236 建银国际金融有限公司 CE AJO225 Guosen Securities (HK) Capital Company Limited CE AUX600 Fosun International Securities Limited CE AAF432 PATRONS SECURITIES LIMITED CE BPQ161 BOCI ASIA LIMITED CE AET863 Eddid Securities and Futures Limited CE BHT550 农银国际证券有限公司 CE ACX411 VALUABLE CAPITAL LIMITED CE AUL711 富途证券国际(香港)有限公司 CE AZT137 CNCB (Hong Kong) Capital Limited CE AEQ982 CENTRAL CHINA INTERNATIONAL CAPITAL LIMITED CE ABC734 Dragonstone Capital Management Limited CE BGM303
Joint Lead Managers (16)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 国泰君安证券(香港)有限公司 CE ABY236 建银国际金融有限公司 CE AJO225 Guosen Securities (HK) Capital Company Limited CE AUX600 Fosun International Securities Limited CE AAF432 PATRONS SECURITIES LIMITED CE BPQ161 BOCI ASIA LIMITED CE AET863 Eddid Securities and Futures Limited CE BHT550 农银国际证券有限公司 CE ACX411 VALUABLE CAPITAL LIMITED CE AUL711 富途证券国际(香港)有限公司 CE AZT137 CNCB (Hong Kong) Capital Limited CE AEQ982 CENTRAL CHINA INTERNATIONAL CAPITAL LIMITED CE ABC734 Dragonstone Capital Management Limited CE BGM303 广发证券(香港)经纪有限公司 CE AOB364 CEB International Capital Corporation Limited CE BGH296

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Harvest International Premium Value (Secondary Market) Fund SPC 156,993,920 HKD — 46.09% — 6 months 2023-11-08

Directors & Management

PositionChinese nameEnglish Name
Chairman孔健—
Company Secretary劉斯宇,賴浩恩—
No director data available.

Major Shareholders

Major Shareholders & Holdings孔健(28.79%);張琰平(9.98%);北京亦莊生物醫藥并購投資中心(有限合伙)(9.70%);北京亦莊二期生物醫藥產業投資基金(有限合伙)(9.05%);北京賽升藥業股份有限公司(6.79%);珠海橫琴綠竹企業管理合伙企業(有限合伙)(6.08%);建銀國際資本管理(天津)有限公司(5.76%)
About this page

This page shows Luzhu Biotech-B (02480) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect